Shares in the NYSE-listed company dropped 2.8% at market open following the earnings, possibly a reflection of 2025 guidance.

Abbott stock reversed early losses Wednesday on its strong sales outlook for 2025 and a bullish performance from its diabetes ...

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...

Adding a monoclonal antibody cocktail to the standard treatment for inoperable liver cancer nearly doubled the amount of time ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects ...

Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated ...

Much of the discussion at GSMC will be about the impact of Donald Trump's second presidency on seafood trade. UCN team in ...

Pennsylvania has several neighbors with legal adult-use sales, including Delaware, Maryland, New Jersey, New York and Ohio.